A5009302642- Inflammatory Bowel Disease
- Microscopic Colitis
- Diverticular Disease and Complications
- Anorectal Disease Treatments and Outcomes
- Eosinophilic Esophagitis
- Diagnosis and treatment of tuberculosis
- Autoimmune and Inflammatory Disorders
- Liver Disease Diagnosis and Treatment
- Pharmaceutical studies and practices
- Liver Diseases and Immunity
- Helicobacter pylori-related gastroenterology studies
- Celiac Disease Research and Management
- Immunodeficiency and Autoimmune Disorders
- Colorectal and Anal Carcinomas
- IL-33, ST2, and ILC Pathways
- Tuberculosis Research and Epidemiology
- Gastrointestinal motility and disorders
- Health Systems, Economic Evaluations, Quality of Life
- Colorectal Cancer Screening and Detection
- Biosimilars and Bioanalytical Methods
- SARS-CoV-2 and COVID-19 Research
- Chronic Lymphocytic Leukemia Research
- Hidradenitis Suppurativa and Treatments
- Pharmacovigilance and Adverse Drug Reactions
- Pancreatitis Pathology and Treatment
Washington University in St. Louis
2017-2025
Bahawal Victoria Hospital
2025
Aalborg University
2024
Christian Medical College, Vellore
2024
Uttarakhand Technical University
2024
Glenmark Pharmaceuticals (India)
2024
Perrigo (United States)
2024
Bristol-Myers Squibb (Switzerland)
2024
Entasis Therapeutics (United States)
2024
AbbVie (United States)
2024
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly introduced antibody and vaccine countermeasures. Here, using monoclonal antibodies (mAbs), animal immune sera, human convalescent sera from recipients of BNT162b2 mRNA vaccine, we report impact on neutralization a panel authentic including B.1.1.7 isolate, chimeric strains with South African or Brazilian spike genes isogenic...
Patients with chronic inflammatory disease (CID) treated immunosuppressive medications have increased risk for severe COVID-19. Although mRNA-based SARS-CoV-2 vaccination provides protection in immunocompetent persons, immunogenicity immunosuppressed patients CID is unclear.To determine the of vaccines CID.Prospective observational cohort study.Two U.S. referral centers.Volunteer sample adults confirmed eligible early COVID-19 vaccination, including hospital employees any age and older than...
Alterations of the mycobiota composition associated with Crohn's disease (CD) are challenging to link defining elements pathophysiology, such as poor injury repair. Using culture-dependent and -independent methods, we discovered that Debaryomyces hansenii preferentially localized was abundant within incompletely healed intestinal wounds mice inflamed mucosal tissues CD human subjects. D. cultures from injured impaired colonic healing when introduced into conventionally raised or gnotobiotic...
ABSTRACT Background Individuals with chronic inflammatory diseases (CID) are frequently treated immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2 vaccination platforms provide robust protection in immunocompetent individuals, the immunogenicity CID patients on immunosuppression is not well established. Therefore, determining effectiveness vaccines setting essential to risk-stratify impaired and clinical guidance regarding...
The risk of non-Hodgkin's lymphoma (NHL) with tumor necrosis factor alpha (TNF-α) inhibitors is unclear, whether related to concomitant thiopurines usage or due the underlying inflammatory disease. We sought review all cases T-cell NHL reported Food and Drug Administration (FDA) in patients receiving TNF-α for approved indications examine comparison use bowel disease (IBD).The FDA Adverse Event Reporting System (AERS) was queried lymphomas following treatment inhibitors: infliximab,...
OBJECTIVES: Crohn's disease (CD) management targets mucosal healing on ileocolonoscopy as a treatment goal. We hypothesized that radiologic response is also associated with better long-term outcomes. METHODS: Small bowel CD patients between 1 January 2002 and 31 October 2014 were identified. All had pre-therapy computed tomography enterography (CTE)/magnetic resonance (MRE) follow-up CTE or MRE after 6 months, 2 CTE/MREs≥6 months apart while maintenance therapy. Radiologists characterized...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global COVID-19 pandemic infecting more than 106 million people and causing 2.3 deaths. The rapid deployment of antibody-based countermeasures provided hope for curtailing disease ending
Combining biologics and small molecules could potentially overcome the plateau of drug efficacy in inflammatory bowel disease (IBD). We conducted a systematic review meta-analysis to assess safety effectiveness dual biologic therapy (DBT), or molecule combined with (SBT) IBD patients.
Background Hepatosplenic T-cell lymphoma (HSTCL) is a rare, lethal disease generally seen in young male patients with inflammatory bowel disease. The study of biologic and immunomodulator naive Crohn's (SONIC), advocates combining infliximab an moderate-to-severe Unfortunately, combined immunosuppression increases risk for HSTCL. We herein review all cases HSTCL reported to the Food Drug Administration (FDA) receiving TNF-α inhibitors. Methods Individual reports from FDA Adverse Event...
Background The association between inhibition of tumour necrosis factor alpha (TNF-α) and new onset neurological adverse events (AEs) is unclear. Aims To evaluate AEs with TNF-α inhibitors reported to the Food Drug Administration Adverse Event Reporting System (FAERS) utilising a standardised scoring tool for drug-induced AEs. Methods A search FAERS (January 1, 2000 December 31, 2009) infliximab, adalimumab, certolizumab etanercept was performed. Full-text reports were accessed using Freedom...
Crohn's disease (CD) of the pouch and chronic pouchitis occur in approximately 10% patients after ileal pouch–anal anastomosis (IPAA) for refractory ulcerative colitis (UC) or UC-related dysplasia. The efficacy anti–tumor necrosis factor (anti-TNF) agents vedolizumab have been reported treatment CD pouchitis, but little is known regarding use ustekinumab these settings. Our primary aim was to evaluate conditions. This a retrospective, multicenter cohort study evaluating with pouchitis....
Abstract Background and Aims Inflammation of the pouch after ileal pouch-anal anastomosis (IPAA) can significantly impact quality life be difficult to treat. We assessed effectiveness safety vedolizumab in Crohn’s disease (CD) chronic antibiotic-dependent or antibiotic-refractory pouchitis. Methods This was a retrospective, multicenter cohort study at 5 academic referral centers United States. Adult patients with endoscopic inflammation who received were included. The primary outcome...
Group 3 innate lymphoid cells (ILC3s) are key players in intestinal homeostasis. Endoplasmic reticulum (ER) stress is linked to inflammatory bowel disease (IBD). Herein, we used cell culture, mouse models, and human specimens examine if ER ILC3s impacts IBD pathophysiology. We show that exhibited a 24h-rhythmic expression pattern of the master response regulator, IRE1α/XBP1. Proinflammatory cytokine IL-23 selectively stimulated IRE1α/XBP1 through mitochondrial reactive oxygen species...
Abstract Background Perianal fistulizing Crohn’s disease (pfCD) poses a significant challenge, requiring precise endpoints in clinical trials to evaluate the effectiveness of therapies. While Magnetic Resonance Imaging (MRI) is gold standard for assessing fistula healing, variability radiological definitions complicates trial design and real-world treatment evaluations. This study aimed achieve international consensus on definition healing pfCD. Methods two-phase was conducted by Treatment...
Abstract Background The interleukin (IL)-23 signaling is a vital pathway in Crohn’s disease (CD). IL-23 activates T-helper (Th) 17 cells, IL-17-secreting CD8 T (Tc)17 γδ natural killer (NK) and group 3 innate lymphoid cells (ILC3) to secrete inflammatory cytokines including IL-17, IFN-γ, TNF-α. Risankizumab the first selective antagonist approved for moderate-to-severe CD; however, no biomarker currently exists predict response this medication. Here, we characterized phenotypes of...
We aimed to describe the real-world effectiveness and safety of upadacitinib (UPA), an oral Janus kinase 1 inhibitor (JAKi) in patients with Crohn's disease (CD). A retrospective analysis was conducted across nine centers United States, focusing on adults CD treated UPA 45 mg as induction therapy for active luminal disease. The co-primary endpoints were clinical remission at 12 weeks (Harvey Bradshaw Index ≤ 4 or absence symptoms physician's global assessment) endoscopic 6 months (SEMA-CD...